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the analysis was restricted to patients who had received
≥4 prescriptions in the 6 months prior to their ﬁrst lan-
soprazole 15mg prescription (25%: 31/122). Amongst
those patients with a speciﬁc diagnosis of GORD/RO,
37% (15/41) switched to a higher dose PPI within 6
months. Around half (52%; 16/31) of patients who
returned to a higher dose had no speciﬁc reason recorded
(16/31). However the most commonly recorded reason
for failing on lansoprazole 15mg was inadequate control
of symptoms (35%; 11/31). CONCLUSION: The pro-
portion of patients changed from standard or high dose
PPI to lansoprazole 15mg who required an increase in
PPI therapy within 6 months was higher than that re-
ported for patients treated with esomeprazole 20mg.
PGS3
META-ANALYSIS OF PPI-BASED TRIPLE
THERAPY FOR THE ERADICATION OF
HELICOBACTER PYLORI
Edwards SJ, Plumb JM
AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom
OBJECTIVE: The recommended treatment for Heli-
cobacter pylori eradication in the UK is a proton pump
inhibitor (PPI) in combination with amoxicillin 1g and
clarithromycin 500mg all twice daily for 7 days. The aim
of this analysis was to compare the efﬁcacies of the rec-
ommended PPI-based triple therapies for the eradication
of H. pylori using omeprazole-based triple therapy as a
common comparator. METHODS: The PPIs licensed in
the UK for twice daily triple therapy are esomeprazole 
20mg (EAC), lansoprazole 30mg (LAC), omeprazole 
20mg (OAC), pantoprazole 40mg (PAC), and rabepra-
zole 20mg (RAC). A meta-analysis of randomised con-
trolled trials comparing a 7-day regimen of PPI-based
triple therapies was conducted using omeprazole-based
triple therapy as a common comparator. Data on eradi-
cation rates were extracted and re-analysed, where
required, to provide “intention-to-treat” results. The
primary method of calculating the summary effect esti-
mates used a Fixed Effects model. A chi-squared test was
used to assess heterogeneity for each comparison. A sec-
ondary analysis comparing 7-day regimens of PPI plus
any dose of amoxycillin and clarithromycin was con-
ducted to test the robustness of the results. RESULTS:
The alternative strategies, compared with OAC, provided
the following results—EAC (Relative Risk 1.01; 95%
Conﬁdence Interval: 0.95 to 1.08), LAC (RR 1.05; 95%
CI: 0.94 to 1.17), PAC (RR 0.92; 95% CI: 0.80 to 1.06).
No trials comparing rabeprazole with omeprazole using
UK recommended triple therapy were found. Signiﬁcant
heterogeneity was detected in the LAC comparison with
OAC and so these results should be treated with caution.
The secondary analysis conﬁrmed that there was no sig-
niﬁcant difference in the four alternative strategies 
compared to OAC. CONCLUSIONS: No PPI-based
triple therapy was found to be signiﬁcantly more efﬁca-
cious than omeprazole-based triple therapy. However,
esomeprazole 20mg is the only PPI licensed in the UK for
triple therapy that would be considered a low dose.
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OBJECTIVE: Evidence-based techniques were applied to
clinical trial data of esomeprazole for maintaining healed
erosive esophagitis (EE) to provide a practical, quantita-
tive analysis of its efﬁcacy relative to lansoprazole.
METHODS: Patients with a history of heartburn and EE,
Los Angeles Grade A–D at baseline, received esomepra-
zole 40mg once daily for up to 8 weeks for healing. Those
with healed EE were randomized to receive once daily
esomeprazole 20mg (n = 615) or lansoprazole 15mg 
(n = 609) for up to 6 months. For this retrospective analy-
sis, the number needed to treat (NNT), the reciprocal of
the absolute risk reduction (ARR), was calculated at 6
months for all patients and for subgroups with mild
disease (LA Grade A or B) and severe disease (LA Grade
C or D). RESULTS: In this evidence-based analysis, it 
was determined that 11 patients with EE would need to
be treated with esomeprazole to prevent one treatment
failure that otherwise may occur with lansoprazole
regardless of the baseline grade of EE. As the severity of
disease increased (LA Grade C or D), the NNT to prevent
one relapse that may otherwise have occurred with lan-
soprazole decreased to 6. CONCLUSIONS: For patients
with more severe disease, the NNT was lower, indicating
a greater likelihood of therapeutic success with esome-
prazole versus lansoprazole. This evidence supports
esomeprazole as an effective treatment for maintenance
of remission and prevention of treatment failure in gas-
troesophageal reﬂux disease patients with EE.
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OBJECTIVE: Estimate the burden of IBS comparing
resource use between IBS-patients (IBSp) and non-IBS
subjects(controls) during a 1-year follow up. METHODS:
Observational, prospective study including 517 IBSp,
meeting Rome II criteria, and 84 controls. Controls were
selected from those subjects who had attended a health
centre due to digestive problems (excluding IBS). Both
samples were selected from the consulting ofﬁces of 92
Spanish gastroenterologists and Primary Care Physicians.
IBSp and controls attended a total of 5 visits at 3 month
intervals. During ﬁrst month after each visit patients
recorded drug utilization and indirect resource in a
diarycard. Direct resource was collected by investigators
in follow-up medical controls. RESULTS: Mean patients
age (SD) was 43 (14) years and 75% were female. No dif-
ferences in age and gender were observed between IBSp
and controls. 90% of IBSp and 100% of controls visited
a clinic at least once (p < 0.01), but only IBSp (52%) did
it due to abdominal pain. Hospitalizations were registered
in 7.5% of IBSp and 2.9% of controls. Thirty-eight
percent of IBSp and 15% of control were assisted in an
emergency guard at least once (p < 0.01); abdominal pain
was the main reason for IBSp to attend the emergency
guard (11%). 43% of IBSp required some speciﬁc test 
due to their abdominal pathology (blood samples, gas-
troscopy or colonoscopy). Mean patient cost associated
with resources used was much higher in IBSp (€413.39)
than in controls (€143.94) (p < 0.01). In terms of indirect
resources, 59% of IBSp and 26% of controls experienced
limited or reduced performance at work (p < 0.01). Mean
patient cost associated with absence from work at one
year was also much higher for IBSp (€502.21€) than for
controls (€109.70) (p < 0.01). CONCLUSIONS: This
prospective 1-year follow-up study conﬁrms that IBS is
associated with an important burden in terms of direct
and indirect costs and that IBSp use more health resources
and experience higher productivity loss compared with
non-IBS.
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OBJECTIVE: The primary objective of this multicenter,
randomised, open study was to assess the difference in
direct medical costs incurred over a 6-months period with
a 20mg esomeprazole on-demand maintenance strategy,
compared to a 20mg q.d. continuous therapy. Secondary
objectives were to assess GERD symptoms and to
measure patient satisfaction during the maintenance
phase. METHODS: In total, 2884 patients with uninves-
tigated GERD entered the study and received esomepra-
zole 40mg q.d for 4 weeks. At the end of the acute treat-
ment phase 93% patients were symptom free (complete
resolution of heartburn or not more than 1 day with mild
heartburn during the last 7 days prior to the visit), 
and were randomised to receive either continuous or 
on-demand treatment (esomeprazole 20mg) during a 
6-month maintenance phase (1315 and 1325 patients
respectively). Analyses were performed on an intention to
treat basis. Direct costs include study, OTC and other
GERD medication, unscheduled visits and GERD tests.
RESULTS: The proportion of patients heartburn free at
6 months was signiﬁcantly higher (p < 0.001) in the con-
tinuous treatment with esomeprazole 20mg (86.1%) than
in the on demand group (78.0%). Patient’s satisfaction
reached 94% after the 4 weeks acute treatment and
remained 92% in the maintenance phase, similar in both
groups. Both treatment arms were well tolerated. Mean
daily direct costs were signiﬁcantly lower (P < 0.001) in
the on demand group (€0.96 +/- 0.54 SD) than in the
esomeprazole 20mg q.d. arm (€1.39 +/- 0.31 SD). The
proportion of patients taking GERD-related drugs was
similar in the two groups (8.0% vs 7.3%, p = 0.6). CON-
CLUSIONS: Continuous or on-demand treatment in
patients with uninvestigated GERD offer effective and
safe symptom control with a high patient satisfaction.
On-demand treatment allows signiﬁcant reduction in
medical costs. Choice of treatment should be considered
on patient basis.
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OBJECTIVES: To compare the pharmaceutical costs 
of a new proposal of reimbursement of proton pump
inhibitors (PPI) in the treatment of GERD with the
present regulation in which PPI’s are reimbursed only
when endoscopy demonstrates esophagitis. The new
reimbursement proposal includes empiric therapy
(without endoscopy), symptomatic treatment of non-
erosive GERD, and chronic “on-demand” therapy.
METHODS: A decision tree model was developed for
treatment of patients with GERD resistant to H2 recep-
tor antagonists. Calculations were performed using MS
Excel. Response rates of different therapies and proba-
bilities of ﬁndings at endoscopy were derived from liter-
ature. Costs from the payer’s perspective were calculated
for the ﬁrst 48 weeks of treatment using the mean price
of the PPI on the Belgian market on Jan 1st 2003.
RESULTS: The present reimbursement system and the
new proposal represented a mean 48 weeks cost per 
case of respectively €351 and €204. Sensitivity analysis
